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A B S T R A C T
OBJECTIVE: Review evidence supporting the role of mast cells in migraine patho-
physiology.
BACKGROUND: Mast cells are known for their role in allergic reactions, but they are 
also important in immunity and inflammatory diseases, especially those precipitated 
or worsened by stress. Such are migraine headaches that are associated with spread-
ing neuronal depression and neurogenic inflammation intracranially. Migraines are 
also comorbid with allergies and could precipitate acute coronary syndromes (ACS). 
Mast cells are located perivascularly, in close association with neurons, especially in 
the meninges. Mast cells can be activated by trigeminal nerve stimulation and by acute 
stress, leading to increased vascular permeability and neurogenic inflammation de-
pendent on NK-1 receptors, but not necessarily on substance P (SP).
METHODS: We reviewed relevant literature and summarized our own findings.
RESULTS: Corticotropin-releasing hormone (CRH), a mediator of the stress response 
released from the hypothalamus, can activate CRH receptors either on the sensory 
nuclei of the trigeminal nerve or directly on the mast cells. They, then release proin-
flammatory, nociceptive and vasoactive mediators including histamine, tryptase and 
vascular endothelial growth factor (VEGF), thereby triggering migraine headaches.
CONCLUSIONS: These results indicate that there are several novel points of interven-
tion for the development of therapeutic agents to help alleviate migraines. Preliminary 
clinical studies with brain mast cell blockers and CRH receptor antagonists suggest 
that they could be useful prophylactically.
1 .  S E L E C T I V E  R E L E A S E  O F  M A S T  C E L L  M E D I A T O R S
Mast cells derive from a distinct precursor in the bone marrow1 and mature under 
local tissue microenvironmental factors.2 Mast cells are necessary for the development 
of allergic reactions, through crosslinking of their surface receptors for IgE (FcRI), 
leading to degranulation and the release of vasoactive, pro-inflammatory and nocicep-
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Figure 1. Schematic representation of the sequence of events 
that may induce brain mast cell activation and neurogenic in-
flammation, leading to migraines.
TABLE 1. Mast cell Triggers
Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences
tive mediators that include histamine, cytokines and proteolytic 
enzymes (Table 1).3,4 The multitude of mediators that could 
be secreted, especially in response to many non-immunologic 
triggers (Table 2) has given rise to new speculations about the 
possible role of mast cells in immune responses, especially 
acquired immunity5 and inflammation.6
Unlike allergic reactions, mast cells are rarely seen to 
degranulate during autoimmune7 or inflammatory proc-
esses.8 Instead, mast cells can secrete mediators without overt 
degranulation,9 through differential or selective release,10 
probably regulated by the action of distinct protein kinases 
on a unique phosphoprotein.11,12 In such cases, mast cells 
undergo ultrastructural alterations of their electron dense 
granular core indicative of secretion, but without overt de-
granulation, a process that has been termed “activation”,13-15 
“intragranular activation”16 or “piecemeal” degranulation.17 
Selective release has been reported for a number of media-
tors,18-20 especially serotonin,10 eicosanoids21-23 or IL-6.24-27 In 
fact, we showed that interleukin-1 (IL-1) can stimulate human 
mast cells to release IL-6 selectively without degranulation, 
through a unique process utilizing 40-80 nm vesicles unrelated 
to the secretory granules (800-1000 nm).28 We also recently 
showed that corticotropin releasing hormone (CRH) secreted 
under stress can stimulate human mast cells through specific 
CRH receptors to release vascular endothelial growth factor 
(VEGF) selectively.29
These findings suggest that mast cells may also be involved 
in inflammatory diseases6,30 that include migraines31 and car-
diovascular disease.32
2 .  M E N I N G E A L  I N F L A M M A T I O N  
A N D  M I G R A I N E S
Migraine headache is still a descriptive term that has been 
used primarily to refer to the brain and is usually associated 
with meningeal and cerebral vasodilation, as well as “spread-
ing” neuronal depression.33 It was hypothesized that mast cells 
may be involved in the pathophysiology of migraines.31 Mast 
cells are located in close apposition to neurons in the meninges 
34,35 and can be activated by neuropeptides,36 by antidromic 
nerve stimulation,14 as well as by acute immobilization stress.15 
Brain mast cells were also activated by acute stress leading to 
increased vascular permeability,37 effects dependent on mast 
cells and CRH.38
Stress is known to precipitate or exacerbate migraines, rais-
ing the possibility of some underlying pathologic mechanism. 
One such possibility comes from one study of children mi-
graineurs, in whom the frequency and severity of migraines was 
reduced, along with the unique mast cell biochemical marker 
tryptase, when they were taught relaxation techniques.39 Re-
cent studies have shown that stress-induced neurogenic inflam-
mation depends on NK-1 receptors, but does not require SP,40 
while it may involve a direct action of CRH on brain micro-
vessels.41 Yet, delayed responses may also involve IL-6 and 
nitric oxide elevations in dura macrophages.42 These findings 
have led to a new model for the pathogenesis of intracranial 
neurogenic inflammation (Fig. 1) that calls for hypothalamic 
CRH acting on the sensory nucleus of the trigeminal nerve, 
which has been reported to express CRH receptors;43 CRH 
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TABLE 2. Mast Cell Mediators
Mediators Main Pathophysiologic Effects
Prestored
Biogenic Amines
Histamine Vasodilation, angiogenesis, mitogenesis, pain
5-Hydroxytryptamine (5-HT, serotonin) Vasoconstriction, pain
Chemokines
IL-8, MCP-1, MCP-3, MCP-4, RANTES Chemoattraction and tissue infiltration of leukocytes
Enzymes
Arylsulfatases Lipid/proteoglycan hydrolysis
Carboxypeptidase A Peptide processing
Chymase Tissue damage, angiotensin II synthesis, cholesterol liberation
Kinogenases Synthesis of vasodilatory kinins, pain
Phospholipases Arachidonic acid generation
Tryptase Tissue damage, activation of PAR, inflammation, pain
Peptides
Corticotropin-releasing hormone (CRH) Inflammation, vasodilation
Endorphins Analgesia
Endothelin Sepsis
Kinins (bradykinin) Inflammation, pain, vasodilation
Somatostatin (SRIF) Anti-inflammatory (?)
Substance P (SP) Inflammation, pain
Vasoactive intestinal peptide (VIP) Vasodilation
Urocortin Inflammation, vasodilation
Vascular endothelial growth factor (VGEF) Neovascularization, vasodilation
Proteoglycans
Chondroitin sulfate Cartilage synthesis, anti-inflammatory
Heparin Angiogenesis, nerve growth factor stabilization
Hyaluronic acid Connective tissue, nerve growth factor stabilization
De novo synthesized
Cytokines
Interleukins (IL)-1,2,3,4,5,6,9,10,13,16 Inflammation, leukocyte migration, pain
INF-γ; MIF; TNF-α Inflammation, leukocyte proliferation/activation
Growth Factors
SCF, GM-CSF, b-FGF, NGF, VEGF Growth of a variety of cells
Phospholipid metabolites
Leukotriene B4 LTB4 Leukocyte chemotaxis
Leukotriene C4 (LTC4) Vasoconstriction, pain
Platelet activating factor (PAF) Platelet activation, vasodilation
Prostaglandin D2 (PGD2) Bronchonstriction, pain
Nitric oxide (NO) Vasodilation
CRH = corticotropin-releasing hormone TGF-β = transforming growth factor-β
CSF = colony stimulating factor TNF-α = tumor necrosis factor-α
INFγ = Interferon-γ SRIF = somatomedin release inhibitory factor, somatostatin
MIF = macrophage inflammatory factor GM-CSF = granulocyte monocyte-colony stimulating factor
b-FGF = fibroblast growth factor NGF = nerve growth factor
SCF = Stem cell factor VEGF = vascular endothelial growth factor
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could then secrete mast cell stimulating peptides and/or have 
a direct action on mast cells and/or on the vasculature.6 These 
processes have recently been reviewed,44 as has been the im-
portant role of mast cells in migraine pathophysiology.45
C O N C L U S I O N
In summary, the mast cell has emerged as a unique immune 
cell that could be activated by many non-immune processes, 
including acute stress, 46 and could participate in a variety of 
inflammatory diseases including the brain. 30
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